Medicus Pharma Ltd. Partners with Gorlin Syndrome Alliance for SKINJECT™

Medicus Pharma Ltd. has announced a collaboration with the Gorlin Syndrome Alliance to expand access to SKINJECT™, an investigational treatment for Gorlin Syndrome. This rare genetic disorder leads patients to develop numerous basal cell carcinomas (BCCs), necessitating frequent surgical interventions. SKINJECT™ is a novel precision therapy aimed at treating non-melanoma skin diseases, specifically BCCs.

The partnership seeks FDA approval for the Expanded Access IND Program, allowing patients to access SKINJECT™ under supervised protocols. This initiative is intended to collect real-world data to bolster future regulatory filings and incorporate patient-driven insights into the drug's development.

Medicus is also conducting a Phase 2 clinical trial, SKNJCT-003, in the U.S., with promising interim results. The company continues to advance its research in both the United States and internationally.